Amryt Pharma PLC

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland.

In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former executives from Amryt Pharma, underscoring its commitment to advancing its clinical assets. Chairman Cathal Friel, who co-founded both Poolbeg and Amryt, will spearhead a similar strategic approach followed by Amryt, which successfully developed drugs for unmet medical and bought in commercial assets before being sold for just shy of $1.5bn.

Poolbeg Pharma beefs up leadership; brings key players from succesful Amryt Pharma team

PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.

Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 milestones that pay out $1 and $1.50 on certain conditions.

Amryt Pharma: Final Chance To Pick Up An Attractive CVR

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amryt Pharma Plc (NASDAQ: AMYT) to Chiesi Farmaceutici S.p.A. is fair to Amryt shareholders. Per the terms of the proposed transaction, Chiesi would acquire Amryt for $14.50 in cash per American Depositary Share (ADS) of Amryt plus Contingent Value Rights of up to $2.50 per ADS payable if certain milestones related to Amryt's product Filsuvez® are achieved.

AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amryt Pharma Plc (NasdaqGS: AMYT) to Chiesi Farmaceutici S.p.A. Under the terms of the proposed transaction, shareholders of Amryt will receive $14.50 in cash plus a Contingent Value Right of up to $2.

AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT

A MRYT P UBLISHES SCHEME CIRCULAR A ND ANNOUNCES T HE SHAREHOLDER MEETINGS T O CONSIDER A ND VOTE O N T HE CHIESI ACQUISITION W ILL B E H ELD O N MARCH 22, 2023

AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023

A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.

Why Shares of Amryt Pharma Jumped This Week

Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones.

Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers

Wilmington, Delaware--(Newsfile Corp. - January 10, 2023) - Rigrodsky Law, P.A. is investigating Amryt Pharma Plc ("Amryt") (NASDAQ: AMYT) regarding possible breaches of fiduciary duties and other violations of law related to Amryt's agreement to be acquired by Chiesi Farmaceutici S.p.A.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-amryt-pharma-plc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc Buyout

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Amryt Pharma Plc (NASDAQ: AMYT), relating to its proposed sale to Chiesi Farmaceutici SpA. Under the terms of the agreement, AMYT shareholders are expected to receive $14.50 plus one Contingent Value Right of up to $2.50 per American Depositary Share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Amryt Pharma Plc - AMYT

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc. All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

COMP A dopts P ositive O pinion on O rphan D esignation for Mycapssa® for the T reatment of C arcinoid S yndrome A ssociated with N euroendocrine T umors

COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors

European Commission approves Mycapssa ® for the t reatment of Acromegaly

European Commission approves Mycapssa® for the treatment of Acromegaly

Amryt Announces New Patent for Mycapssa ®

Amryt Announces New Patent for Mycapssa®

Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon - CFO, COO & Company Secretary Sheila Frame - President, Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Edward Nash - Canaccord Genuity Catherine Novack - Jones Research Brian White - Shore Capital Group Douglas Tsao - H.C. Wainwright & Co. Operator Good morning, and welcome to the Amryt Pharma Q3 2022 Results Call and Webcast.

Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of -50% and 7.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Lags Revenue Estimates

Amryt Supports Acromegaly Awareness Day 202 2

Amryt Supports Acromegaly Awareness Day 2022

Amryt Pharma PLC Sponsored ADR (AMYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

The British Journal of Dermatology Publishes Results f rom Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

The British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

Amryt Supports Global EB Awareness Week 202 2

Amryt Supports Global EB Awareness Week 2022

A mryt to Report Q 3 202 2 Results on November 3 , 2022

Amryt to Report Q3 2022 Results on November 3, 2022

COMP adopts positive opinion on O rphan D isease D esignation for Mycapssa® for the treatment of Acromegaly

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

News for Amryt Pharma PLC Stock (AMYT)